Evaluation of AIbZIPand Cdc47 as markers for human prostatic diseases

OBJECTIVES Benign prostatic hyperplasia and prostate cancer are important public health issues. However, histologic markers for these diseases are limited. METHODS Immunocytochemistry was used to analyze the cellular localization of AlbZIP, Cdc47, androgen receptor and estrogen receptor-beta markers. AlbZIP is a protein recently found to be more abundant in prostate cancer than in benign prostatic tissue, and Cdc47 is a cell proliferation-associated protein. The localization and modulation of androgen receptor and estrogen receptor-beta through the carcinogenesis process have been examined in several Studies but controversial results were obtained. These four proteins were evaluated as potential markers of prostatic diseases in 210 needle core biopsies, including normal prostate, benign prostatic hyperplasia, low-grade and high-grade prostatic intraepithelial neoplasia, and different Gleason grades of prostatic adenocarcinoma. RESULTS Androgen receptor and estrogen receptor-beta do not discriminate between benign and malignant specimens, while AlbZIP was able to distinguish between them. Cdc47, in contrast, discriminated not only between malignant and benign prostatic tissue, but also between benign prostatic hyperplasia and normal prostatic tissue. CONCLUSIONS Cdc47 appears to be a sensitive marker of prostatic diseases since its expression gradually increased in parallel with the severity of the lesion. AlbZIP discriminated between benign tissue and cancer. AlbZIP and Cdc47 thus appear to be useful markers with diagnostic and prognostic values. (c) 2007 Elsevier Inc.